RB depletion is required for the continuous growth of tumors initiated by loss of RB

The retinoblastoma (RB) tumor suppressor is functionally inactivated in a wide range of human tumors where this inactivation promotes tumorigenesis in part by allowing uncontrolled proliferation. RB has been extensively studied, but its mechanisms of action in normal and cancer cells remain only partly understood. Here, we describe a new mouse model to investigate the consequences of RB depletion and its re-activation in vivo. In these mice, induction of shRNA molecules targeting RB for knock-down results in the development of phenotypes similar to Rb knock-out mice, including the development of pituitary and thyroid tumors. Re-expression of RB leads to cell cycle arrest in cancer cells and repression of transcriptional programs driven by E2F activity. Thus, continuous RB loss is required for the maintenance of tumor phenotypes initiated by loss of RB, and this new mouse model will provide a new platform to investigate RB function in vivo.

[1]  E. Knudsen,et al.  Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition , 2020, Cancer Research.

[2]  N. Park,et al.  Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence , 2020, Cancers.

[3]  Ken-ichiro Hayashi,et al.  The auxin-inducible degron 2 technology provides sharp degradation control in yeast, mammalian cells, and mice , 2020, Nature Communications.

[4]  W. Sellers,et al.  Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders , 2020, Nature Cancer.

[5]  J. Sage,et al.  Integrating Old and New Paradigms of G1/S Control. , 2020, Molecular cell.

[6]  Jianmin Wang,et al.  Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer , 2020, Gut.

[7]  E. Winer,et al.  The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer. , 2020, Cancer discovery.

[8]  S. Blain,et al.  The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer , 2020, Molecular Cancer Therapeutics.

[9]  P. Fasching,et al.  Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. , 2019, The New England journal of medicine.

[10]  M. Mino‐Kenudson,et al.  PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kα inhibitors in breast cancer. , 2019, Cancer discovery.

[11]  P. Neven,et al.  The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 , 2019, JAMA oncology.

[12]  G. Leone,et al.  The broken cycle: E2F dysfunction in cancer , 2019, Nature Reviews Cancer.

[13]  D. Feldser,et al.  RB constrains lineage fidelity and multiple stages of tumour progression and metastasis , 2019, Nature.

[14]  M. Gobbi,et al.  Plasma and Brain Concentrations of Doxycycline after Single and Repeated Doses in Wild-Type and APP23 Mice , 2018, The Journal of Pharmacology and Experimental Therapeutics.

[15]  S. Loi,et al.  Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer , 2018, The New England journal of medicine.

[16]  M. Salto‐Tellez,et al.  Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath digital image analysis , 2018, Histopathology.

[17]  J. Sage,et al.  Beyond the Cell Cycle: Enhancing the Immune Surveillance of Tumors Via CDK4/6 Inhibition , 2018, Molecular Cancer Research.

[18]  M. Fischer,et al.  Census and evaluation of p53 target genes , 2017, Oncogene.

[19]  P. Sicinski,et al.  Cell cycle proteins as promising targets in cancer therapy , 2017, Nature Reviews Cancer.

[20]  Henry W. Long,et al.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.

[21]  M. Rubin,et al.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.

[22]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[23]  N. Dyson RB1: a prototype tumor suppressor and an enigma , 2016, Genes & development.

[24]  Tuan S. Nguyen,et al.  Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. , 2016, Cancer discovery.

[25]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[26]  G. Shapiro,et al.  Targeting CDK4 and CDK6: From Discovery to Therapy. , 2016, Cancer discovery.

[27]  Lukas E. Dow,et al.  Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas , 2016, Proceedings of the National Academy of Sciences.

[28]  D. Feldser,et al.  Recombinase-based conditional and reversible gene regulation via XTR alleles , 2015, Nature Communications.

[29]  Hans Clevers,et al.  Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer , 2015, Cell.

[30]  A. Brunet,et al.  Inhibition of pluripotency networks by the Rb tumor suppressor restricts reprogramming and tumorigenesis. , 2015, Cell stem cell.

[31]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[32]  Christof Fellmann,et al.  An optimized microRNA backbone for effective single-copy RNAi. , 2013, Cell reports.

[33]  Simon Pieraut,et al.  Inducible control of gene expression with destabilized Cre , 2013, Nature Methods.

[34]  Christof Fellmann,et al.  A pipeline for the generation of shRNA transgenic mice , 2012, Nature Protocols.

[35]  Matko Bosnjak,et al.  REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms , 2011, PloS one.

[36]  Johannes Zuber,et al.  A Rapid and Scalable System for Studying Gene Function in Mice Using Conditional RNA Interference , 2011, Cell.

[37]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[38]  Israel Steinfeld,et al.  BMC Bioinformatics BioMed Central , 2008 .

[39]  Y. Katayama,et al.  Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas , 2007, Journal of Neuro-Oncology.

[40]  R. Bronson,et al.  Selective Requirements for E2f3 in the Development and Tumorigenicity of Rb-Deficient Chimeric Tissues , 2007, Molecular and Cellular Biology.

[41]  T. Jacks,et al.  The Related Retinoblastoma (pRb) and p130 Proteins Cooperate to Regulate Homeostasis in the Intestinal Epithelium* , 2006, Journal of Biological Chemistry.

[42]  Rudolf Jaenisch,et al.  Efficient method to generate single‐copy transgenic mice by site‐specific integration in embryonic stem cells , 2006, Genesis.

[43]  Y. Katayama,et al.  The p15INK4b/p16INK4a/RB1 Pathway Is Frequently Deregulated in Human Pituitary Adenomas , 2005 .

[44]  C. Sherr,et al.  Principles of Tumor Suppression , 2004, Cell.

[45]  R. Bronson,et al.  E2F3 Loss Has Opposing Effects on Different pRB-Deficient Tumors, Resulting in Suppression of Pituitary Tumors but Metastasis of Medullary Thyroid Carcinomas , 2003, Molecular and Cellular Biology.

[46]  T. Rosol,et al.  Rb function in extraembryonic lineages suppresses apoptosis in the CNS of Rb-deficient mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Michael C. Ostrowski,et al.  Extra-embryonic function of Rb is essential for embryonic development and viability , 2003, Nature.

[48]  Joseph B. Rayman,et al.  E2F4 loss suppresses tumorigenesis in Rb mutant mice. , 2002, Cancer cell.

[49]  T. Jacks,et al.  Tumor Suppression by a Severely Truncated Species of Retinoblastoma Protein , 2002, Molecular and Cellular Biology.

[50]  W. Farrell,et al.  Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. , 2000, Cancer research.

[51]  W. Lee,et al.  RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/- mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[52]  M. Vooijs,et al.  Flp-mediated tissue-specific inactivation of the retinoblastoma tumor suppressor gene in the mouse , 1998, Oncogene.

[53]  C. Sherr Cancer Cell Cycles , 1996, Science.

[54]  D. Harrison,et al.  Effects of heterozygosity for the Rb-1t19neo allele in the mouse. , 1995, Oncogene.

[55]  D. Riley,et al.  Quantitative effects of the retinoblastoma gene on mouse development and tissue-specific tumorigenesis. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[56]  Y. Chen,et al.  Expression of a retinoblastoma transgene results in dwarf mice. , 1993, Genes & development.

[57]  R. Weinberg,et al.  Effects of an Rb mutation in the mouse , 1992, Nature.

[58]  A. Berns,et al.  Requirement for a functional Rb-1 gene in murine development , 1992, Nature.

[59]  C. Sherr,et al.  The D-Type Cyclins: A Historical Perspective , 2018 .

[60]  G. Shapiro,et al.  Targeting CDK 4 and CDK 6 : From Discovery to Therapy , 2015 .

[61]  S. M. Rubin Deciphering the retinoblastoma protein phosphorylation code. , 2013, Trends in biochemical sciences.

[62]  HighWire Press Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research. , 2002 .